Abstract
Eighty-two patients were randomly allocated to receive intravenous acyclovir 5 mg kg-1 t.d.s. for 23 days followed by oral acyclovir 800 mg 6-hourly for 6 months or matching placebos after allogeneic bone marrow transplantation. Herpes simplex and varicella zoster virus infections were significantly reduced during the period of administration of acyclovir. No reduction in cytomegalovirus infection was demonstrated. The drug was not toxic.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 24 print issues and online access
$259.00 per year
only $10.79 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Selby, P., Powles, R., Easton, D. et al. The prophylactic role of intravenous and long-term oral acyclovir after allogeneic bone marrow transplantation. Br J Cancer 59, 434–438 (1989). https://doi.org/10.1038/bjc.1989.88
Issue Date:
DOI: https://doi.org/10.1038/bjc.1989.88
This article is cited by
-
Duration of Antiviral Prophylaxis and Risk of Herpes Zoster among Patients Receiving Autologous Hematopoietic Stem Cell Transplants: A Retrospective, Observational Study
Advances in Therapy (2017)
-
Frequency of varicella zoster virus infection in allogeneic stem cell transplant patients: case series from a single centre
Drugs & Therapy Perspectives (2016)
-
Cytomegalovirus infection/disease after hematopoietic stem cell transplantation
International Journal of Hematology (2010)
-
The effect of low-dose aciclovir on reactivation of varicella zoster virus after allogeneic haemopoietic stem cell transplantation
Bone Marrow Transplantation (2005)
-
Cellular immunotherapy for viral infection after HSC transplantation
Nature Reviews Immunology (2005)
